Galapagos NV

Galapagos NV (PINKSHEETS:GLPYY) Wellcome Trust grant makes software publicly available to researchers

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 22 July 2008 - Galapagos NV (Euronext: GLPG) announced today that the U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos' service division BioFocus DPI for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) until December 2010. According to the terms of this agreement, Galapagos will receive more than $9 million (€5.7 million) over the course of the two year extension.

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 18 July 2008 - Galapagos NV (Euronext: GLPG) announced today that it has reached the first milestone in its osteoporosis collaboration with Eli Lilly and Company (NYSE:LLY), triggering a payment of €1 million from Lilly.

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 17 July 2008 - Galapagos NV (Euronext: GLPG) announced today that Boehringer Ingelheim has exercised its right to license two drug targets from the autoimmune research agreement with Galapagos' BioFocus DPI service division, resulting in a milestone payment to Galapagos.

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 2 July 2008 - Galapagos NV (Euronext: GLPG) announced today that its Board of Directors on 26 June 2008 has created and offered 250,065 warrants under a new warrant plan for Galapagos employees and consultants. Furthermore, the Extraordinary General Shareholders' Meeting (EGM) held on 26 June 2008 approved the offer of 57,500 warrants for the benefit of directors of the company.

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 30 June 2008 - Galapagos NV (Euronext: GLPG) announces today that its service division BioFocus DPI will provide compound management and related services to Sepracor Inc. (NASDAQ: SEPR), a leader in respiratory and central nervous system disorder medicines. Total contract value for Galapagos is €1 million ($1.5 million). Under the terms of the agreement, BioFocus DPI will receive, register, and store selected compounds from Sepracor's proprietary compound library, and plate and replicate these compounds for a period of three years. Services will be provided by BioFocus DPI's compound management facility in South San Francisco, USA.

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 16 June 2008 - Galapagos NV (Euronext: GLPG) announced today that it has reached two new milestones in its multi-year drug discovery alliance with GlaxoSmithKline in osteoarthritis, triggering a payment of €0.8 million from GSK.

Galapagos NV (PINKSHEETS:GLPYY) Mechelen, Belgium; 3 June 2008 - Galapagos NV (Euronext: GLPG) announced today that its Annual General Shareholders' meeting approved Dr. William Garth Rapeport's appointment to the Board of Directors of Galapagos.